secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0001193125-23-157864
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon announces proposed public offering and concurrent private placement to fund INPEFA launch
--------------------------------------------------------------------------------

- FDA approved INPEFA (sotagliflozin) on May 26, 2023 for heart failure and type 2 diabetes with CKD.
- Company expects commercial availability by end of June; sales team booked over 5,000 appointments.
- Proposed underwritten public offering of common stock; concurrent private placement to Invus affiliate.
- Net proceeds to fund commercial launch of INPEFA, R&D, and working capital.
- Bookrunners: Citigroup, Jefferies, Piper Sandler; 30-day over-allotment option to underwriters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000119312523157864/0001193125-23-157864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000119312523157864/d507509d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-157864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer